Literature DB >> 16904189

Diagnostic validity of assessment scales for depression in patients with schizophrenia.

Sung-Wan Kim1, Su-Jung Kim, Bo-Hyun Yoon, Jae-Min Kim, Il-Seon Shin, Michael Y Hwang, Jin-Sang Yoon.   

Abstract

The aim of this study was to examine the diagnostic validity of four commonly used assessment scales for depression in schizophrenia. The study population consisted of 84 inpatients meeting the DSM-IV criteria for schizophrenia. Depression in the study subjects was defined by the DSM-IV criteria for major depressive episode. The Positive and Negative Syndrome Scale (PANSS) and the Simpson-Angus Rating Scale (SARS) were used to differentiate depression from the negative and extrapyramidal symptom-related depressive phenomena in schizophrenia. The following four depression scales were assessed for their diagnostic validity as measures of depressive disorder in schizophrenia: the Calgary Depression Scale for Schizophrenia (CDSS), the Beck Depression Inventory (BDI), the Hamilton Rating Scale for Depression (HAM-D), and the depression subscale of the PANSS (PANSS-D). Of 84 patients with schizophrenia, 32 were diagnosed as having comorbid depressive disorder. The areas under the Receiver Operating Characteristic (ROC) curves of the CDSS, HAM-D, PANSS-D, and BDI were 0.94, 0.89, 0.90, and 0.81, respectively. The area under the ROC curve of the CDSS was significantly greater than that of the BDI and tended to be more favorable than those for the HAM-D and the PANSS-D. Our study suggests that the CDSS may provide the best assessment for depression in patients with schizophrenia.

Entities:  

Mesh:

Year:  2006        PMID: 16904189     DOI: 10.1016/j.psychres.2005.10.002

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  22 in total

1.  Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia.

Authors:  Wolfram An der Heiden; Anne Leber; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-23       Impact factor: 5.270

2.  Screening for negative symptoms: preliminary results from the self-report version of the Clinical Assessment Interview for Negative Symptoms.

Authors:  Stephanie G Park; Katiah Llerena; Julie M McCarthy; Shannon M Couture; Melanie E Bennett; Jack J Blanchard
Journal:  Schizophr Res       Date:  2012-01-21       Impact factor: 4.939

3.  Insight, self-stigma and psychosocial outcomes in Schizophrenia: a structural equation modelling approach.

Authors:  Y-J Lien; H-A Chang; Y-C Kao; N-S Tzeng; C-W Lu; C-H Loh
Journal:  Epidemiol Psychiatr Sci       Date:  2016-12-15       Impact factor: 6.892

4.  The Role of Insight in Moderating the Association Between Depressive Symptoms in People With Schizophrenia and Stigma Among Their Nearest Relatives: A Pilot Study.

Authors:  Dzmitry Krupchanka; Mikhail Katliar
Journal:  Schizophr Bull       Date:  2016-03-12       Impact factor: 9.306

5.  Negative expectancy appraisals and defeatist performance beliefs and negative symptoms of schizophrenia.

Authors:  Shannon M Couture; Jack J Blanchard; Melanie E Bennett
Journal:  Psychiatry Res       Date:  2011-06-24       Impact factor: 3.222

6.  Psychosocial factors contributing to suicidal ideation in hospitalized schizophrenia patients in Korea.

Authors:  Sung-Wan Kim; Su-Jung Kim; Ji-Woong Mun; Kyung-Yeol Bae; Jae-Min Kim; Seon-Young Kim; Su-Jin Yang; Il-Seon Shin; Jin-Sang Yoon
Journal:  Psychiatry Investig       Date:  2010-05-04       Impact factor: 2.505

7.  Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.

Authors:  Deanna L Kelly; David A Gorelick; Robert R Conley; Douglas L Boggs; Jared Linthicum; Fang Liu; Stephanie Feldman; M Patricia Ball; Heidi J Wehring; Robert P McMahon; Marilyn A Huestis; Stephen J Heishman; Kimberly R Warren; Robert W Buchanan
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

8.  The Motivation and Pleasure Scale-Self-Report (MAP-SR): reliability and validity of a self-report measure of negative symptoms.

Authors:  Katiah Llerena; Stephanie G Park; Julie M McCarthy; Shannon M Couture; Melanie E Bennett; Jack J Blanchard
Journal:  Compr Psychiatry       Date:  2013-01-22       Impact factor: 3.735

9.  Assessment of trait and state aspects of depression in schizophrenia.

Authors:  Joshua Chiappelli; Katie L Nugent; Kavita Thangavelu; Katherine Searcy; L Elliot Hong
Journal:  Schizophr Bull       Date:  2013-05-17       Impact factor: 9.306

10.  Structural differences within negative and depressive syndrome dimensions in schizophrenia, organic brain disease, and major depression: A confirmatory factor analysis of the positive and negative syndrome scale.

Authors:  Daniel P Eisenberg; Dmitry B Aniskin; Leonard White; Judith A Stein; Philip D Harvey; Igor I Galynker
Journal:  Psychopathology       Date:  2009-05-16       Impact factor: 1.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.